Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Almotriptan products are in shortage in Canada (1 of 10 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A triptan used to treat migraine headaches.
Products affected
1 / 10
In shortage since
Jan 16, 2026
Reports on file
23
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · since Jan 16, 2026, est. end Jan 23, 2026 · Disruption of the manufacture of the drug.
Resolved
SANDOZ ALMOTRIPTAN
12.5MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02405334 · ended May 4, 2026 · Disruption of the manufacture of the drug.
Discontinued
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849
Resolved
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849 · ended Jun 16, 2025 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ALMOTRIPTAN
6.25MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398435 · ended Mar 22, 2024 · Shortage of an active ingredient.
Resolved
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · ended Mar 20, 2024 · Shortage of an active ingredient.
Resolved
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849 · ended Jun 20, 2023 · Disruption of the manufacture of the drug.
Resolved
MYLAN-ALMOTRIPTAN
12.5MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398443 · ended Mar 22, 2022 · Shortage of an active ingredient.
Resolved
MYLAN-ALMOTRIPTAN
6.25MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02398435 · ended Mar 22, 2022 · Shortage of an active ingredient.
Resolved
ALMOTRIPTAN
12.5MG · TABLET · SANIS HEALTH INC
DIN 02466821 · ended Sep 6, 2019 · Disruption of the manufacture of the drug.
Resolved
TEVA-ALMOTRIPTAN
12.5MG · TABLET · TEVA CANADA LIMITED
DIN 02434849 · ended Aug 28, 2019 · Requirements related to complying with good manufacturing practices.
Resolved
APO-ALMOTRIPTAN
12.5MG · TABLET · APOTEX INC
DIN 02405806 · ended May 13, 2019 · Disruption of the manufacture of the drug.
Showing 12 of 23 reports. All reports are on file with Health Canada.
What's happening
Almotriptan is currently affected by an active shortage report filed with Health Canada by MYLAN PHARMACEUTICALS ULC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Almotriptan is classified under “ANTIMIGRAINE PREPARATIONS” (ATC N02CC).
Recent changes
No changes recorded yet.
Common questions
What is Almotriptan used for?
A triptan used to treat migraine headaches.
When will Almotriptan be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Almotriptan in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.